Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI could make mental health assessments more reliable

NCT ID NCT06923995

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether an AI tool can accurately measure depression and anxiety symptoms from video interviews. Researchers will compare the AI's ratings to those of human clinicians. The goal is to create a more consistent way to evaluate symptoms in clinical trials, which could help bring new treatments to patients faster. The study involves 120 adults in the US who are starting treatment for depression or anxiety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-driven clinical interview
What this could lead to
If successful, this could lead to more consistent and objective mental health assessments, speeding up the development of new treatments for depression and anxiety.
What could go wrong
This is an early-stage study focused on measurement, not treatment. The AI may not match human accuracy across all groups, and results may not generalize beyond this specific tool.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Feb 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * English fluency * 18 to 65 years of age. * HAM-D 17 \> 10 * Starting, or has started, a new treatment for depression or anxiety within 2-3 weeks of enrollment * Access to a laptop or other computer with a well functioning microphone and webcam, and a stable Internet connection * Stated willingness to comply with all study procedures and availability for the duration of the study * Resides in the United States at the time of consent and during completion of study Exclusion Criteria: * Any cognitive impairment that limits ability to provide informed consent or authorization * Vulnerable or protected populations (e.g. prisoners) * Impairment that would prevent participants from completing an online survey and/or engaging in clinician assessment interviews (e.g., visual impairment, motor impairment, hearing impairment) * Acute intoxication at the time of the assessments * Concurrent medication/treatment: * Receiving any fast-acting treatment for depression or anxiety (e.g. ketamine, psychedelics, deep brain stimulation, etc.) in between initial baseline assessment (A1) and Restest (A2) , or in between Follow up assessment (B1) and Retest (B2) * Anxiolytics: Use of benzodiazepines or other anxiety-reducing medications that could affect speech or motor activity, within the past 4 weeks. * Antipsychotics and Mood Stabilizers: Medications that can alter cognitive and motor functions, within the past 6 weeks. * Stimulants: Use of medications like methylphenidate or amphetamines that affect energy levels and behavior, within the past 2 weeks * Epilepsy medication: seizure activity or medication side effects that may alter behavior, within the past 4 weeks. * Any history or evidence of any of the following conditions: * Neurodevelopmental, Neurocognitive, Neurodegenerative or movement disorders including, but not limited to: * Tourette's syndrome * Multiple Sclerosis * Amyotrophic Lateral Sclerosis * Parkinson's Disease * Stroke * Traumatic Brain Injury * Facial paralysis. * Conditions with vocal cord impact: * Vocal cord injury or cerebrovascular accident or head trauma with residual dysarthria in the past year * Disorders that may impact vocal cords such as acute or chronic laryngitis, vocal cord paresis or paralysis, or spasmodic dysphonia * Past or active heavy smokers (an average of \>20 cigarettes per day) * Schizophrenia Spectrum and Other Psychotic Disorders: * Individuals with a current or past diagnosis of Schizophrenia, Schizoaffective Disorder, or other psychotic disorders, including Delusional Disorder and Brief Psychotic Disorder. * Current hypomanic episode as defined by DSM-5 criteria. This includes those with Bipolar I Disorder, Bipolar II Disorder, or Cyclothymic Disorder who are not in a stable mood state at the time of assessment. * Chronic Pain Conditions: Such as fibromyalgia, which may affect facial expressions and vocal tone. * Prosthetic Facial Devices: Could affect facial recognition algorithms. Cosmetic Procedures: Such as Botox injections or facelifts that can impact facial expressions. * Dental Work: Major procedures that might affect speech. * Participants who have previously participated in another research project by Deliberate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Baylor College of Medicine

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.